Trial site
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu 211199, ChinaNot linked to an institution yet
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 2/34 trials
- Phase 12 trials
- Phase 22 trials
- Phase 1/21 trial
- Phase 31 trial
- Status
- Recruiting6 trials
- Not yet recruiting3 trials
- Active, not recruiting2 trials
- Lead sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.2 trials
- Abbisko Therapeutics Co, Ltd1 trial
- Acepodia Biotech, Inc.1 trial
- Huahui Health1 trial
- Hutchmed1 trial
- and 5 more
Running trials
Recruiting
Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
NCT07861425· Phase 1· Acepodia Biotech, Inc.· Source
Contact: Acepodia Clinical Team
Recruiting
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
NCT07813572· Phase 3· Suzhou Zelgen Biopharmaceuticals Co.,Ltd· Source
Contact: Shukui Qin
Recruiting
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
NCT07547553· Phase 1/2· Huahui Health· Source
Contact: Xiyu Zhang PM
Not yet recruiting
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
NCT07392866· Phase 2/3· Nanjing Sanhome Pharmaceutical, Co., Ltd.· Source
Contact: Shukui Qin
Recruiting
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
NCT07310173· Phase 2· Zhejiang Hisun Pharmaceutical Co. Ltd.· Source
Contact: Chen Xun
Active, not recruiting
Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
NCT07300488· Phase 2/3· Xi'an Xintong Pharmaceutical Research Co.,Ltd.· Source
Active, not recruiting
A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors
NCT07362264· Phase 1· Nanjing Sanhome Pharmaceutical, Co., Ltd.· Source
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Contact: Chen Xun
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Maorong Wang
Recruiting
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888· Phase 2/3· Hutchmed· Source
Contact: Shukui Qin
Not yet recruiting
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT05976568· Phase 2/3· Qilu Pharmaceutical Co., Ltd.· Source
Contact: Shukui Qin
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error